Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Significant Decrease in Short Interest

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 169,677 shares, a decline of 72.9% from the May 31st total of 625,772 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,555,159 shares, the days-to-cover ratio is currently 0.1 days.

Jupiter Neurosciences Trading Up 19.6%

Shares of Jupiter Neurosciences stock traded up $0.05 during mid-day trading on Friday, hitting $0.28. 20,678,963 shares of the stock were exchanged, compared to its average volume of 3,017,760. Jupiter Neurosciences has a twelve month low of $0.17 and a twelve month high of $3.33. The stock has a market capitalization of $10.27 million, a price-to-earnings ratio of -1.05 and a beta of 1.71. The company has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.56.

Jupiter Neurosciences (NASDAQ:JUNS) last released its earnings results on Thursday, May 14th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.23 million.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Jupiter Neurosciences

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in shares of Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Allen Capital Group LLC acquired a new stake in Jupiter Neurosciences in the 4th quarter valued at $31,000. Yorkville Advisors Global LP acquired a new stake in Jupiter Neurosciences in the 4th quarter valued at $135,000. Finally, Vestor Capital LLC raised its position in Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the period.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.